Friday, March 20, 2026 | 02:06 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Page 4 - Laurus Labs

Buy these mid, smallcap stocks for at least 20% returns in 2022

Laurus Labs Ltd, Endurance Technologies Ltd may surge over 30 per cent whereas small cap stocks like Avanti Feeds Ltd, BASF India and Rain Industries could jump up to 40 per cent from current levels

Buy these mid, smallcap stocks for at least 20% returns in 2022
Updated On : 31 Dec 2021 | 3:38 PM IST

Laurus Labs signs pact to acquire 26.62 % stake in ImmunoACT

Laurus labs investment in ImmunoACT is part of the larger strategy to strengthen biologics business of the firm

Laurus Labs signs pact to acquire 26.62 % stake in ImmunoACT
Updated On : 19 Nov 2021 | 9:53 PM IST

Adani Transmission, Max Financials, Laurus Labs to gain from FTSE rejig

The three stocks are part of several other domestic companies likely to get added to FTSE indices. Adani Transmission is likely to see the largest inflows at $121 million

Adani Transmission, Max Financials, Laurus Labs to gain from FTSE rejig
Updated On : 14 Sep 2021 | 1:18 AM IST

Laurus Labs hits record high; rallies 17% in 7 days post Q1 results

The management holds a positive outlook across all four businesses -- FDF, APIs, Synthesis and Bio -- and believes the outlook remains robust driven by improving demand and supported by capex

Laurus Labs hits record high; rallies 17% in 7 days post Q1 results
Updated On : 09 Aug 2021 | 9:58 AM IST

Laurus Labs rebounds 9% from day's low after 3 straight sessions of decline

The management maintains positive outlook across all four businesses -- FDF, APIs, Synthesis and Bio-- on the back of improving demand, and supported by capacity expansion plans planned

Laurus Labs rebounds 9% from day's low after 3 straight sessions of decline
Updated On : 30 Jul 2021 | 2:25 PM IST

Laurus Labs receives licence from DRDO to manufacture Covid drug 2DG

2DG has been given emergency approval by the Drugs Controller General of India (DCGI) for use on COVID-19 patients in the country, Laurus Labs said in a regulatory filing.

Laurus Labs receives licence from DRDO to manufacture Covid drug 2DG
Updated On : 02 Jul 2021 | 3:01 PM IST

Prospects in key segments to keep Laurus Labs' growth trajectory strong

The stock has seen a six-fold jump in value over the last one year

Prospects in key segments to keep Laurus Labs' growth trajectory strong
Updated On : 01 Jul 2021 | 1:45 AM IST

Laurus Labs rallies 5% on credit rating upgrade; stock hits record high

The company is looking to build new capacities/facilities that would propel its growth in the coming years

Laurus Labs rallies 5% on credit rating upgrade; stock hits record high
Updated On : 25 Jun 2021 | 10:12 AM IST

Laurus Labs gains 2% on robust growth outlook, zooms 70% so far in FY22

The company is looking to build new capacities and facilities that would propel its growth in the coming years

Laurus Labs gains 2% on robust growth outlook, zooms 70% so far in FY22
Updated On : 22 Jun 2021 | 10:12 AM IST

Laurus Labs, Alkyl Amines: More steam left after 1,000% gain from 2020 low?

Laurus Labs is likely to maintain its upward journey as long as it doesn't break the support level of Rs 600 levels

Laurus Labs, Alkyl Amines: More steam left after 1,000% gain from 2020 low?
Updated On : 18 Jun 2021 | 12:00 PM IST

Laurus Labs trades higher for 8th straight day, soars 73% in 3 months

Shares of Laurus Labs continued their upward journey to hit a new high of Rs 599 on the BSE in intra-day trade on Tuesday

Laurus Labs trades higher for 8th straight day, soars 73% in 3 months
Updated On : 08 Jun 2021 | 10:30 AM IST

Laurus Labs shares advance 5% on strong growth outlook

Laurus is well poised to follow the success story of some leading CDMO players backed by strong chemistry and integrated model

Laurus Labs shares advance 5% on strong growth outlook
Updated On : 03 May 2021 | 11:50 AM IST

Laurus Labs hits new high in subdued market, surges 30% in a month

The company is scheduled to meet on April 29, 2021, to consider and approve the audited financial results of the company for the financial year ended March 31, 2021

Laurus Labs hits new high in subdued market, surges 30% in a month
Updated On : 23 Apr 2021 | 1:28 PM IST

Laurus Labs rallies 6%, hits record high on heavy volume

The pharmaceutical company's stock surpassed its previous high of Rs 386, touched on January 25, 2021

Laurus Labs rallies 6%, hits record high on heavy volume
Updated On : 06 Apr 2021 | 10:14 AM IST

Dixon Tech, Adani Green: How to trade multi-baggers of FY21 in new fiscal

Hindustan Copper, Aarti Drugs, Dixon Technology, APL Apollo Tubes, Laurus Labs and Affle India, meanwhile, zoomed over 400 per cent during FY21

Dixon Tech, Adani Green: How to trade multi-baggers of FY21 in new fiscal
Updated On : 01 Apr 2021 | 12:49 PM IST

Laurus Labs falls 5% as promoters sell 1.3% stake in company

Laurus Labs said the significant part of the above amount shall be utilized to release the pledge on their equity shares of the company

Laurus Labs falls 5% as promoters sell 1.3% stake in company
Updated On : 05 Mar 2021 | 2:35 PM IST

Select pharma shares rally; Suven Pharma up 13%, Laurus nears record high

Healthcare companies to post decent growth in revenues in Q3FY21

Select pharma shares rally; Suven Pharma up 13%, Laurus nears record high
Updated On : 14 Jan 2021 | 1:44 PM IST

BSE Healthcare index hits new high; Sun Pharma, Laurus Labs gain up to 5%

Sun Pharmaceutical Industries hit afresh 52-week high of Rs 568.50, up nearly 4 per cent in the intra-day trade today. It has surged 11 per cent in the past four trading days on the BSE

BSE Healthcare index hits new high; Sun Pharma, Laurus Labs gain up to 5%
Updated On : 04 Dec 2020 | 2:47 PM IST

Surprise amid pandemic: Firms across sectors beat Q2 earnings expectations

Most brokerages have revised upwards their earnings estimates, not only for FY21, but also for FY22

Surprise amid pandemic: Firms across sectors beat Q2 earnings expectations
Updated On : 30 Nov 2020 | 10:50 PM IST

Laurus Labs gains 7% in two days on acquisition of Richcore Lifesciences

Motilal Oswal Securities maintains 'buy' rating on Laurus Labs with target price of Rs 410 per share

Laurus Labs gains 7% in two days on acquisition of Richcore Lifesciences
Updated On : 27 Nov 2020 | 10:31 AM IST